Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.54 |
| ▸ | PPARG | P37231 | 8/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | MPC2 | O95563 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6928125 | 1.00 | FFAR1 (0.54) | FFAR1PPARGPPARAMPC2CYP2C8 | |
| SCHEMBL19217891 | 1.00 | FFAR1 (0.54) | FFAR1PPARGPPARAMPC2CYP2C8 | |
| SCHEMBL16311124 | 0.90 | FFAR1 (0.58) | FFAR1PPARGPPARAMPC2CYP2C8 | |
| SCHEMBL6930852 | 0.89 | PPARG (0.69) | FFAR1PPARGPPARAMPC2CYP2C8 | |
| SCHEMBL6930193 | 0.89 | PPARG (0.69) | FFAR1PPARGPPARAMPC2CYP2C8 | |
| SCHEMBL6930317 | 0.89 | PPARG (0.69) | FFAR1PPARGPPARAMPC2CYP2C8 | |
| SCHEMBL6928451 | 0.88 | PPARG (0.58) | FFAR1PPARGPPARAMPC2CYP2C8 | |
| SCHEMBL6928167 | 0.88 | PPARG (0.58) | FFAR1PPARGPPARAMPC2CYP2C8 | |
| SCHEMBL21504741 | 0.88 | PPARG (0.58) | FFAR1PPARGPPARAMPC2CYP2C8 | |
| SCHEMBL19217625 | 0.87 | FFAR1 (0.41) | FFAR1PPARGCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3202401-B1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CIRIUS THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2513070-B1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3202401-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Octeta Therapeutics, LLC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2512470-B1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OCTETA THERAPEUTICS LLC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| US-9126959-B2 | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126959-B2 | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150051406-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-20150051406-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-20120322728-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120316138-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316138-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120309975-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309975-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2011084456-A9 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011084453-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084459-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084456-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011075514-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309975-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | PPARD, PPARG, PPARA | FFAR1 51/4885PPARG 2/4885PPARA 3/4885 |
| US-20150051406-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | PPARD, PPARG, PPARA | FFAR1 51/4885PPARG 2/4885PPARA 3/4885 |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | PPARD, PPARG, PPARA | FFAR1 45/4885PPARG 2/4885PPARA 3/4885 |
| US-20120316138-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | PPARD, PPARA, PPARG | FFAR1 45/4885PPARG 3/4885PPARA 2/4885 |
| US-20120322728-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | GLP1R, PPARD, PPARA | FFAR1 44/4885PPARG 4/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.